^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

BCY11864

i
Other names: BCY11864
Associations
Trials
Company:
Bicycle Therap
Drug class:
CD137 agonist, Nectin-4 inhibitor
Associations
Trials
3years
[VIRTUAL] Microinjection of Nectin-4/CD137 tumor-targeted immune cell agonist (TICA™) activates the local tumor microenvironment (AACR 2021)
Akin to our findings with transcriptional profiling of the tumor response to BT7480, BCY11864 activity was shown not to be limited to T cells but also included other CD137 positive cell populations such as myeloid and NK cells. We hypothesize that tumor targeted CD137 agonism may lead to initial myeloid cell response that enhances the cytotoxic T cell recruitment and activation in the tumor tissue.
IO biomarker
|
CD8 (cluster of differentiation 8) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • TNFRSF9 (TNF Receptor Superfamily Member 9)
|
NECTIN4 expression
|
BCY11864 • BT7480